Accelerated-phase CML: de novo and transformed

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Chronic myeloid leukemia (CML) outcomes have improved, but advanced stages, like blast phase CML (BP-CML), still have poor prognoses.
• BP-CML is infrequent but poorly understood and inadequately treated, necessitating a focus on preventing disease progression.

Purpose of the Study:

• To review current understanding and challenges in managing BP-CML.
• To highlight advances in genomic investigation and novel therapeutic strategies for BP-CML.
• To address the need for improved identification and treatment of high-risk CML patients.

Main Methods:

• Review of recent advances in CML genomics and therapeutics.
• Discussion of diagnostic challenges, including differentiating CML-like ALL from lymphoid BP-CML.
• Exploration of novel treatment approaches like the MATCHPOINT strategy.

Main Results:

• Genomic studies reveal limited understanding of BP-CML biology.
• The concept of "CML-like" ALL aids in differentiating BCR::ABL1-positive ALL from de novo lymphoid BP-CML.
• Novel combination therapies show potential but require further validation.

Conclusions:

• Preventing progression from chronic phase CML to BP-CML remains a primary therapeutic goal.
• Further research is crucial for clarifying identification and treatment strategies for high-risk BP-CML patients.
• Enhanced understanding of BP-CML biology is essential for developing targeted therapies.